Article Text

Download PDFPDF
Guillain–Barré syndrome with antibodies to GD1a/GD1b complex
  1. Tsuyoshi Hamaguchi1,
  2. Kenichi Sakajiri1,
  3. Kenji Sakai1,
  4. Soichi Okino1,
  5. Masami Sada2,
  6. Susumu Kusunoki2
  1. 1Department of Neurology, Ishikawa Prefecture Central Hospital, Kanazawa, Japan
  2. 2Department of Neurology, Kinki University School of Medicine, Osaka-Sayama, Japan
  1. Correspondence to:
 Dr T Hamaguchi
 Department of Neurology, Ishikawa Prefecture Central Hospital, 2-1 Kuratsuki-higashi, Kanazawa 920-8530, Japan; gom56{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Recently, ganglioside complexes (GSCs) such as GD1a/GD1b, GD1a/GM1, GD1b/GT1b, GM1/GT1b, GQ1b/GM1 and GQ1b/GD1a have been shown as target antigens for serum antibodies in patients with Guillain–Barré syndrome (GBS)1 and Miller Fisher syndrome (MFS).2 Gangliosides may interact with each other to form a novel epitope, which serves as a target antigen for serum antibodies.1 In paticular, anti-GD1a/GD1b IgG is reported to be associated with severe GBS and requirement of mechanical ventilation.1 However, there has been no previous case report describing GBS with anti-GSC antibodies in detail. In this report, we present a patient with GBS having anti-GD1a/GD1b antibody and investigated the clinical feature.


A 42-year-old man noticed weakness of the bilateral upper extremities 2 weeks after an episode of acute respiratory tract symptoms and diarrhoea. His symptoms further developed to dysarthria, dysphagia and tetraparesis, and he was admitted to the Department of Neurology, Ishikawa Prefecture …

View Full Text


  • Informed consent was obtained for publication of the patient’s details described in this report.

  • Competing interests: None declared.